Immuron LTD (IMRN) — SEC Filings

Overview

Immuron LTD (IMRN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Dec 16, 2025: Immuron Limited, a pharmaceutical preparations company, filed a Form 6-K on December 16, 2025. This report is for the month of December 2025 and indicates the company files annual reports under Form 20-F. The filing is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Se

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 49 neutral, 1 mixed. The dominant filing sentiment for Immuron LTD is neutral.

Filing Type Overview

Immuron LTD (IMRN) has filed 49 6-K, 1 20-F with the SEC between Dec 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• 6-K Filing — 6-K · Apr 13, 2026
• Immuron Ltd Files 6-K Report — 6-K · Dec 16, 2025 Risk: low
  Immuron Limited, a pharmaceutical preparations company, filed a Form 6-K on December 16, 2025. This report is for the month of December 2025 and indicates the c
• Immuron Ltd Files 6-K Reporting December Announcements — 6-K · Dec 15, 2025 Risk: low
  Immuron Limited, a pharmaceutical company, filed a Form 6-K on December 15, 2025, reporting on two public announcements made during December 2025. The filing in
• 6-K Filing — 6-K · Dec 12, 2025
• Immuron Ltd. Files December 2025 6-K Report — 6-K · Dec 10, 2025 Risk: low
  On December 10, 2025, Immuron Ltd. filed a Form 6-K with the SEC, reporting information for the month of December 2025. The filing indicates that Immuron Limite
• Immuron Ltd Files 6-K for December 2025 — 6-K · Dec 5, 2025 Risk: low
  Immuron Limited filed a Form 6-K on December 5, 2025, reporting on its activities for the month of December 2025. The filing indicates that the company is a for
• 6-K Filing — 6-K · Dec 4, 2025
• Immuron Ltd. Files 6-K Report — 6-K · Dec 3, 2025 Risk: low
  On December 3, 2025, Immuron Ltd. filed a Form 6-K, reporting a public announcement made during the month of December 2025. The filing indicates that Immuron Li
• Immuron Ltd Files November 2025 6-K Report — 6-K · Nov 21, 2025 Risk: low
  Immuron Limited filed a Form 6-K on November 21, 2025, reporting its activities for the month of November 2025. The filing indicates that the company is a forei
• Immuron Ltd Files 6-K for November 2025 — 6-K · Nov 12, 2025 Risk: low
  Immuron Limited filed a Form 6-K on November 12, 2025, reporting on its activities for the month of November 2025. The filing indicates the company is a foreign
• Immuron Ltd. Files 6-K for November Announcements — 6-K · Nov 7, 2025 Risk: low
  On November 7, 2025, Immuron Ltd. filed a Form 6-K to report two public announcements made in November 2025. The filing does not contain specific financial figu
• Immuron Ltd. Files 6-K with SEC — 6-K · Nov 6, 2025 Risk: low
  On November 6, 2025, Immuron Ltd. filed a Form 6-K, reporting on two public announcements made during November 2025. The company is a foreign private issuer and
• 6-K Filing — 6-K · Nov 5, 2025
• Immuron Ltd Files October 2025 6-K Report — 6-K · Oct 31, 2025 Risk: low
  Immuron Limited filed a Form 6-K on October 31, 2025, reporting information for the month of October 2025. The filing indicates the company is a foreign private
• Immuron Ltd Files October 2025 6-K Report — 6-K · Oct 27, 2025 Risk: low
  Immuron Limited filed a Form 6-K on October 27, 2025, reporting its activities for the month of October 2025. The filing indicates that the company is a foreign
• Immuron Ltd Files 6-K for October 2025 — 6-K · Oct 24, 2025 Risk: low
  Immuron Limited filed a Form 6-K on October 24, 2025, reporting on its activities for the month of October 2025. The filing indicates the company is a foreign p
• Immuron Ltd. Files October 2025 Report on Form 6-K — 6-K · Oct 23, 2025 Risk: low
  On October 23, 2025, Immuron Ltd. filed a Form 6-K with the SEC, reporting its activities for the month of October 2025. The filing indicates that the company i
• Immuron Ltd Files 6-K Reporting Published Announcements — 6-K · Oct 21, 2025 Risk: low
  On October 20, 2025, Immuron Limited filed a Form 6-K with the SEC, reporting the publication of two announcements. These announcements are being furnished to t
• Immuron Ltd Files October 2025 6-K Report — 6-K · Oct 20, 2025 Risk: low
  On October 20, 2025, Immuron Limited filed a Form 6-K with the SEC. This report is for the month of October 2025 and indicates that Immuron Limited is a foreign
• Immuron Ltd Files 6-K with October Announcements — 6-K · Oct 17, 2025 Risk: low
  Immuron Limited filed a Form 6-K on October 17, 2025, reporting two public announcements made during October 2025. The company, based in Carlton, Victoria, Aust
• Immuron Ltd Files 6-K for October 2025 Announcements — 6-K · Oct 14, 2025 Risk: low
  Immuron Limited filed a Form 6-K on October 14, 2025, reporting on two public announcements made during October 2025. The company is a foreign private issuer an
• Immuron Ltd Files 6-K with October Announcements — 6-K · Oct 10, 2025 Risk: low
  Immuron Limited filed a Form 6-K on October 10, 2025, reporting two public announcements made during October 2025. The filing indicates that the company is a fo
• Immuron Ltd Files 6-K Report — 6-K · Oct 8, 2025 Risk: low
  Immuron Limited filed a Form 6-K on October 8, 2025, reporting information for the month of October 2025. The filing indicates that the company is a foreign pri
• Immuron Ltd Files Form 6-K for October 2025 — 6-K · Oct 3, 2025 Risk: low
  Immuron Limited announced on July 2, 2024, that it entered into an At The Market Offering. This filing is a Form 6-K, reporting for the month of October 2025, a
• Immuron Ltd Files 6-K Report — 6-K · Oct 2, 2025 Risk: low
  On October 2, 2025, Immuron Limited filed a Form 6-K, reporting on two public announcements made during October 2025. The company is a foreign private issuer an
• Immuron Ltd Files September 2025 6-K Report — 6-K · Sep 30, 2025 Risk: low
  Immuron Limited filed a Form 6-K on September 30, 2025, reporting information for the month of September 2025. The filing includes an auditor's consent as Exhib
• Immuron Ltd. Files 6-K with SEC — 6-K · Sep 26, 2025 Risk: low
  On September 25, 2025, Immuron Ltd. filed a Form 6-K to report two public announcements made during September 2025. The company is a foreign private issuer and
• Immuron Narrows Losses Amid R&D Push, Eyes Future Financing — 20-F · Sep 25, 2025 Risk: high
  Immuron Ltd (IMRN) reported a net loss of A$5,215,987 for the fiscal year ended June 30, 2025, an improvement from A$6,936,957 in 2024 and A$3,786,507 in 2023.
• Immuron Ltd Files 6-K with SEC — 6-K · Sep 16, 2025 Risk: low
  Immuron Limited filed a Form 6-K on September 16, 2025, reporting on announcements made during September 2025. The filing indicates the company is a foreign pri
• Immuron Ltd Files September 2025 6-K Report — 6-K · Sep 2, 2025 Risk: low
  Immuron Limited filed a Form 6-K on September 2, 2025, reporting its activities for the month of September 2025. The filing indicates the company is a foreign p
• Immuron Ltd Files 6-K with SEC — 6-K · Aug 26, 2025 Risk: low
  Immuron Limited, a pharmaceutical company, filed a Form 6-K on August 26, 2025. This report indicates the company is furnishing information to the SEC as a fore
• Immuron Ltd. Files August 2025 Report (6-K) — 6-K · Aug 15, 2025 Risk: low
  On August 15, 2025, Immuron Ltd. filed a Form 6-K, reporting its activities for August 2025. The filing indicates that the company is a foreign private issuer a
• Immuron Ltd Files August 2025 6-K Report — 6-K · Aug 13, 2025 Risk: low
  Immuron Limited filed a Form 6-K on August 13, 2025, reporting on its activities for the month of August 2025. The filing indicates the company is a foreign pri
• Immuron Ltd Files 6-K Report — 6-K · Jul 21, 2025 Risk: low
  Immuron Limited, a pharmaceutical company, filed a Form 6-K on July 21, 2025, reporting on its activities for the month of July 2025. The filing indicates the c
• Immuron Ltd Files July 2025 Report on Form 6-K — 6-K · Jul 18, 2025 Risk: low
  On July 18, 2025, Immuron Limited filed a Form 6-K, reporting its activities for the month of July 2025. The filing indicates that the company is a foreign priv
• Immuron Ltd Files July 2025 Report on Form 6-K — 6-K · Jul 17, 2025 Risk: low
  Immuron Limited filed a Form 6-K on July 17, 2025, reporting its activities for the month of July 2025. The filing indicates the company is a foreign private is
• Immuron Ltd Files 6-K with SEC — 6-K · Jun 4, 2025 Risk: low
  On June 4, 2025, Immuron Limited filed a Form 6-K, reporting on two public announcements made during June 2025. The company, an Australian-based pharmaceutical
• Immuron Ltd Files May 2025 6-K Report — 6-K · May 30, 2025 Risk: low
  Immuron Limited filed a Form 6-K on May 30, 2025, reporting on its activities for the month of May 2025. The filing indicates the company is a foreign private i
• Immuron Ltd Files Form 6-K with SEC — 6-K · Apr 11, 2025 Risk: low
  Immuron Limited filed a Form 6-K on April 11, 2025, reporting three public announcements made during April 2025. The company, based in Carlton, Victoria, Austra
• Immuron Ltd Files 6-K Report — 6-K · Apr 10, 2025 Risk: low
  On April 10, 2025, Immuron Limited filed a Form 6-K to report a public notice. The filing does not contain specific financial figures or new material informatio
• Immuron Ltd Files March 2025 6-K Report — 6-K · Mar 7, 2025 Risk: low
  Immuron Limited filed a Form 6-K on March 7, 2025, reporting its activities for the month of March 2025. The filing indicates that the company is a foreign priv
• Immuron Ltd Files March 2025 6-K Report — 6-K · Mar 5, 2025 Risk: low
  Immuron Limited filed a Form 6-K on March 5, 2025, reporting its activities for the month of March 2025. The filing indicates that the company is a foreign priv
• Immuron Ltd Files February 2025 6-K Report — 6-K · Feb 28, 2025 Risk: low
  Immuron Limited, a pharmaceutical company, filed a Form 6-K on February 28, 2025, reporting on its activities for the month of February 2025. The filing indicat
• Immuron Ltd Files February 2025 6-K Report — 6-K · Feb 19, 2025 Risk: low
  Immuron Limited, a pharmaceutical company, filed a Form 6-K on February 19, 2025, reporting on its activities for February 2025. The filing indicates the compan
• Immuron Ltd Files 6-K Reporting January Announcements — 6-K · Jan 17, 2025 Risk: low
  On January 17, 2025, Immuron Limited filed a Form 6-K, reporting on three announcements made during January 2025. The filing indicates that Immuron is a foreign
• Immuron Ltd Files 6-K Report — 6-K · Jan 15, 2025 Risk: low
  Immuron Limited filed a Form 6-K on January 15, 2025, reporting two published announcements. The filing does not contain specific financial figures or details a
• Immuron Ltd Files January 2025 Report (6-K) — 6-K · Jan 14, 2025 Risk: low
  Immuron Limited filed a Form 6-K on January 14, 2025, reporting its activities for the month of January 2025. The filing indicates that the company is a foreign
• Immuron Ltd Files 6-K with January Announcements — 6-K · Jan 10, 2025 Risk: low
  Immuron Limited filed a Form 6-K on January 10, 2025, reporting two announcements made during January 2025. The filing is for a foreign private issuer and indic
• Immuron Ltd Files 6-K Reporting January Announcement — 6-K · Jan 8, 2025 Risk: low
  Immuron Limited filed a Form 6-K on January 8, 2025, reporting a single announcement published during January 2025. The filing does not specify the content of t
• Immuron Ltd Files 6-K with SEC — 6-K · Dec 10, 2024 Risk: low
  On December 10, 2024, Immuron Limited filed a Form 6-K, reporting the publication of four announcements during the month of December 2024. These announcements a

Risk Profile

Risk Assessment: Of IMRN's 46 recent filings, 1 were flagged as high-risk, 0 as medium-risk, and 45 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Steven Lydeamore

Industry Context

Immuron operates in the biopharmaceutical sector, specifically focusing on the development and commercialization of polyclonal antibodies. The industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies in this space often rely on external financing to fund clinical trials and commercialization efforts.

Top Tags

foreign-private-issuer (31) · 6-K (19) · sec-filing (19) · regulatory-filing (11) · filing (9) · reporting (9) · disclosure (7) · 6-k (7) · announcement (6) · regulatory-update (4)

Key Numbers

• SEC File Number: 001-38104 — Identifies the company's filing with the SEC.
• Net Loss: A$5,215,987 — Fiscal year ended June 30, 2025, an improvement from A$6,936,957 in 2024.
• Accumulated Deficit: A$82,443,205 — As of June 30, 2025, reflecting continuous operating losses since 1994.
• Cash and Cash Equivalents: A$2,830,526 — As of June 30, 2025, indicating need for additional financing.
• Outstanding Ordinary Shares: 233,959,013 — As of June 30, 2025.
• Ordinary Shares per ADS: 40 — Each American Depositary Share represents 40 ordinary shares.
• announcement: 1 — Number of announcements published by Immuron Ltd in February 2025.

Related Companies

IMC

Frequently Asked Questions